366 related articles for article (PubMed ID: 36709130)
1. [Efficacy and safety of Venetoclax in the treatment of 25 patients with recurrent hematologic malignancies after an allogeneic hematopoietic stem cell transplantation].
Chen X; Liu ZY; Zhang RL; Zhai WH; Ma QL; Pang AM; Yang DL; He Y; Wei JL; Feng SZ; Han MZ; Jiang EL
Zhonghua Xue Ye Xue Za Zhi; 2022 Jul; 43(7):542-549. PubMed ID: 36709130
[No Abstract] [Full Text] [Related]
2. Venetoclax combined with hypomethylating agents and the CAG regimen in relapsed/refractory AML: a single-center clinical trial.
Liu Y; Li Y; Zhang R; Yu Z; Jing Y
Front Immunol; 2023; 14():1269163. PubMed ID: 38054008
[TBL] [Abstract][Full Text] [Related]
3. [Short-term efficacy of venetoclax combined with azacitidine in acute myeloid leukemia: a single-institution experience].
Yu WJ; Jia JS; Wang J; Tang FF; Gong LZ; Liu XH; Zhu XL; Zhao XS; Huang XJ; Jiang H
Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):134-140. PubMed ID: 35381674
[No Abstract] [Full Text] [Related]
4. Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome.
Wei Y; Xiong X; Li X; Lu W; He X; Jin X; Sun R; Lyu H; Yuan T; Sun T; Zhao M
Cancer Sci; 2021 Sep; 112(9):3636-3644. PubMed ID: 34185931
[TBL] [Abstract][Full Text] [Related]
5. Interferon-α: A Potentially Effective Treatment for Minimal Residual Disease in Acute Leukemia/Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation.
Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1939-47. PubMed ID: 26116088
[TBL] [Abstract][Full Text] [Related]
6. [Effect of minimal residual disease monitoring by multiparameter flow cytometry pre-conditioning on prognosis of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
Lu Y; Wu T; Wang H; Zhao YL; Cao XY; Liu DY; Zhang JP; Xiong M; Zhou JR; Sun RJ; Wei ZJ; Ji SQ; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2017 Feb; 38(2):118-123. PubMed ID: 28279035
[No Abstract] [Full Text] [Related]
7. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
8. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
[TBL] [Abstract][Full Text] [Related]
9. Outcome after allogeneic hematopoietic stem cell transplantation following Venetoclax-based therapy among AML and MDS patients.
Yang TT; Song XL; Zhao YM; Ye BD; Luo Y; Xiao HW; Chen Y; Fu HR; Yu J; Liu LZ; Lai XY; Ye YS; Lan JP; Huang H; Shi JM
Ann Hematol; 2022 Dec; 101(12):2731-2741. PubMed ID: 36318288
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy and safety of IAC regimen for relapse/refractory acute myeloid leukemia: a prospective randomized controlled study].
Li CH; Wei SN; Qiu SW; Gong BF; Gong XY; Li Y; Liu YT; Fang QY; Zhang GJ; Liu KQ; Zhou CL; Lin D; Liu BC; Wang Y; Mi YC; Wei H; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2022 Apr; 43(4):287-292. PubMed ID: 35680626
[No Abstract] [Full Text] [Related]
11. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors of second hematopoietic allogeneic stem cell transplantation among hematological malignancy patients relapsed after first hematopoietic stem cell transplantation: A single center study.
Lu Y; Zhang JP; Zhao YL; Xiong M; Sun RJ; Cao XY; Wei ZJ; Zhou JR; Liu DY; Yang JF; Zhang X; Lu DP; Lu P
Front Immunol; 2022; 13():1066748. PubMed ID: 36685540
[TBL] [Abstract][Full Text] [Related]
13. Preemptive interferon-α therapy could prevent relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation: A real-world analysis.
Fan S; Pan TZ; Dou LP; Zhao YM; Zhang XH; Xu LP; Wang Y; Huang XJ; Mo XD
Front Immunol; 2023; 14():1091014. PubMed ID: 36817493
[TBL] [Abstract][Full Text] [Related]
14. Preemptive Interferon-α Therapy Could Protect Against Relapse and Improve Survival of Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: Long-Term Results of Two Registry Studies.
Shen MZ; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Zhao XS; Qin YZ; Chang YJ; Liu KY; Huang XJ; Mo XD
Front Immunol; 2022; 13():757002. PubMed ID: 35154096
[TBL] [Abstract][Full Text] [Related]
15. Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy.
Chen W; Ma Y; Shen Z; Chen H; Ma R; Yan D; Shi M; Wang X; Song X; Sun C; Cao J; Cheng H; Zhu F; Sun H; Li D; Li Z; Zheng J; Xu K; Sang W
Front Immunol; 2021; 12():755549. PubMed ID: 34777367
[TBL] [Abstract][Full Text] [Related]
16. [Allogeneic hematopoietic stem cell transplantation in acute leukemia patients with the SET-NUP214 fusion gene: Efficacy and survival analysis].
Xia J; Zhao Y; Chen F; Miao M; Qiu HY; Ma X; Tang XW; Wang Y; Wu XJ; Fu ZZ; Wu DP; Chen SN
Zhonghua Nei Ke Za Zhi; 2023 Apr; 62(4):410-415. PubMed ID: 37032136
[No Abstract] [Full Text] [Related]
17. Case Report: Preemptive Treatment With Low-Dose PD-1 Blockade and Azacitidine for Molecular Relapsed Acute Myeloid Leukemia With RUNX1-RUNX1T1 After Allogeneic Hematopoietic Stem Cell Transplantation.
Tang Y; Zhou Z; Yan H; You Y
Front Immunol; 2022; 13():810284. PubMed ID: 35185899
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy and Survival of Venetoclax Based Regimen in the Treatment of Acute Myeloid Leukemia].
Kong FC; Qi L; Huang WF; Yu M; Zhou YL; Ji DX; Li F
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1676-1683. PubMed ID: 38071045
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy and safety of chimeric antigen receptor T-cell therapy followed by allogeneic hematopoietic stem cell transplantation in 21 patients with Ph-like acute lymphoblastic leukemia].
Dai HP; Shen HJ; Li Z; Cui W; Cui QY; Li MY; Chen SF; Zhu MQ; Wu DP; Tang XW
Zhonghua Xue Ye Xue Za Zhi; 2024 Jan; 45(1):35-40. PubMed ID: 38527836
[No Abstract] [Full Text] [Related]
20. Interferon-α Is Effective for Treatment of Minimal Residual Disease in Patients with t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Registry Study.
Mo XD; Wang Y; Zhang XH; Xu LP; Yan CH; Chen H; Chen YH; Qin YZ; Liu KY; Huang XJ
Oncologist; 2018 Nov; 23(11):1349-1357. PubMed ID: 30076280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]